Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Elizabeth Kessler to Antineoplastic Agents

This is a "connection" page, showing publications Elizabeth Kessler has written about Antineoplastic Agents.

 
Connection Strength
 
 
 
0.911
 
  1. Kessler ER. Management of Metastatic Prostate Cancer in Frail/Elderly Patients. Oncology (Williston Park). 2018 11 15; 32(11):570-3.
    View in: PubMed
    Score: 0.300
  2. Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today (Barc). 2012 Oct; 48(10):633-44.
    View in: PubMed
    Score: 0.196
  3. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Ju?rez VM, Hsieh JJ, Basso U, Shah AY, Su?rez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Zolnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021 03 04; 384(9):829-841.
    View in: PubMed
    Score: 0.088
  4. Neuwelt AJ, Mathur S, Johnson AT, Kessler ER, Bowles DW. Cabozantinib use in renal cell carcinoma. Drugs Today (Barc). 2017 May; 53(5):299-307.
    View in: PubMed
    Score: 0.067
  5. Loh KP, Mohile SG, Kessler E, Fung C. Treatment of Metastatic Prostate Cancer in Older Adults. Curr Oncol Rep. 2016 10; 18(10):63.
    View in: PubMed
    Score: 0.065
  6. Verdoorn BP, Kessler ER, Flaig TW. Targeted therapy in advanced urothelial carcinoma. Oncology (Williston Park). 2013 Mar; 27(3):219-26.
    View in: PubMed
    Score: 0.050
  7. Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glod? LM, Flaig TW. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res. 2013 Jan 01; 19(1):148-57.
    View in: PubMed
    Score: 0.050
  8. Kessler ER, Flaig TW. Optimal management of recurrent prostate cancer in older patients. Drugs Aging. 2012 Nov; 29(11):871-83.
    View in: PubMed
    Score: 0.049
  9. Bowles DW, Kessler ER, Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today (Barc). 2011 Nov; 47(11):857-68.
    View in: PubMed
    Score: 0.046
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)